Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.
Financial Results:
Neuland Laboratories Ltd reported Revenues for Q3FY24 of ₹393.00 Crores up from ₹269.00 Crore year on year, a rise of 46.1%.
Total Expenses for Q3FY24 of ₹291.00 Crores up from ₹231.00 Crores year on year, a rise of 25.97%.
Consolidated Net Profit of ₹81.00 Crores up 161.29% from ₹31.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹63.44, up 166.44% from ₹23.81 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.